List of Tables
Table 1. Drugs for Non-Small Cell Lung Cancer Market Trends
Table 2. Drugs for Non-Small Cell Lung Cancer Market Drivers & Opportunity
Table 3. Drugs for Non-Small Cell Lung Cancer Market Challenges
Table 4. Drugs for Non-Small Cell Lung Cancer Market Restraints
Table 5. Global Drugs for Non-Small Cell Lung Cancer Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Drugs for Non-Small Cell Lung Cancer Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Drugs for Non-Small Cell Lung Cancer Product Type
Table 9. Key Companies Time to Begin Mass Production of Drugs for Non-Small Cell Lung Cancer
Table 10. Global Drugs for Non-Small Cell Lung Cancer Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Non-Small Cell Lung Cancer as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Drugs for Non-Small Cell Lung Cancer Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Drugs for Non-Small Cell Lung Cancer Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Drugs for Non-Small Cell Lung Cancer Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Drugs for Non-Small Cell Lung Cancer Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Drugs for Non-Small Cell Lung Cancer Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Drugs for Non-Small Cell Lung Cancer Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Drugs for Non-Small Cell Lung Cancer Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Drugs for Non-Small Cell Lung Cancer Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Drugs for Non-Small Cell Lung Cancer Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Drugs for Non-Small Cell Lung Cancer Sales Value by Region (2019-2024) & (%)
Table 27. Global Drugs for Non-Small Cell Lung Cancer Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Drugs for Non-Small Cell Lung Cancer Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Drugs for Non-Small Cell Lung Cancer Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Drugs for Non-Small Cell Lung Cancer Sales Value, (2025-2030) & (US$ Million)
Table 31. Bristol-Myers Squibb Basic Information List
Table 32. Bristol-Myers Squibb Description and Business Overview
Table 33. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 34. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Bristol-Myers Squibb (2019-2024)
Table 35. Bristol-Myers Squibb Recent Developments
Table 36. GlaxoSmithKline Basic Information List
Table 37. GlaxoSmithKline Description and Business Overview
Table 38. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 39. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of GlaxoSmithKline (2019-2024)
Table 40. GlaxoSmithKline Recent Developments
Table 41. Menarini Basic Information List
Table 42. Menarini Description and Business Overview
Table 43. Menarini Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 44. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Menarini (2019-2024)
Table 45. Menarini Recent Developments
Table 46. Sanofi Basic Information List
Table 47. Sanofi Description and Business Overview
Table 48. Sanofi Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 49. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Sanofi (2019-2024)
Table 50. Sanofi Recent Developments
Table 51. Ziopharm Oncology Basic Information List
Table 52. Ziopharm Oncology Description and Business Overview
Table 53. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 54. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Ziopharm Oncology (2019-2024)
Table 55. Ziopharm Oncology Recent Developments
Table 56. Alchemia Basic Information List
Table 57. Alchemia Description and Business Overview
Table 58. Alchemia Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 59. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Alchemia (2019-2024)
Table 60. Alchemia Recent Developments
Table 61. Amgen Basic Information List
Table 62. Amgen Description and Business Overview
Table 63. Amgen Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 64. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Amgen (2019-2024)
Table 65. Amgen Recent Developments
Table 66. Apotex Basic Information List
Table 67. Apotex Description and Business Overview
Table 68. Apotex Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 69. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Apotex (2019-2024)
Table 70. Apotex Recent Developments
Table 71. BioMarin Pharmaceutical Basic Information List
Table 72. BioMarin Pharmaceutical Description and Business Overview
Table 73. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 74. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of BioMarin Pharmaceutical (2019-2024)
Table 75. BioMarin Pharmaceutical Recent Developments
Table 76. CellAct Pharma Basic Information List
Table 77. CellAct Pharma Description and Business Overview
Table 78. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 79. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of CellAct Pharma (2019-2024)
Table 80. CellAct Pharma Recent Developments
Table 81. Cerulean Pharma Basic Information List
Table 82. Cerulean Pharma Description and Business Overview
Table 83. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 84. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Cerulean Pharma (2019-2024)
Table 85. Cerulean Pharma Recent Developments
Table 86. Cipla Basic Information List
Table 87. Cipla Description and Business Overview
Table 88. Cipla Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 89. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Cipla (2019-2024)
Table 90. Cipla Recent Developments
Table 91. Cornerstone Pharmaceuticals Basic Information List
Table 92. Cornerstone Pharmaceuticals Description and Business Overview
Table 93. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 94. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Cornerstone Pharmaceuticals (2019-2024)
Table 95. Cornerstone Pharmaceuticals Recent Developments
Table 96. Curis Basic Information List
Table 97. Curis Description and Business Overview
Table 98. Curis Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 99. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Curis (2019-2024)
Table 100. Curis Recent Developments
Table 101. CytRx Basic Information List
Table 102. CytRx Description and Business Overview
Table 103. CytRx Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 104. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of CytRx (2019-2024)
Table 105. CytRx Recent Developments
Table 106. Eli Lilly Basic Information List
Table 107. Eli Lilly Description and Business Overview
Table 108. Eli Lilly Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 109. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Eli Lilly (2019-2024)
Table 110. Eli Lilly Recent Developments
Table 111. Exelixis Basic Information List
Table 112. Exelixis Description and Business Overview
Table 113. Exelixis Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 114. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Exelixis (2019-2024)
Table 115. Exelixis Recent Developments
Table 116. Fresenius Kabi Basic Information List
Table 117. Fresenius Kabi Description and Business Overview
Table 118. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 119. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Fresenius Kabi (2019-2024)
Table 120. Fresenius Kabi Recent Developments
Table 121. Genentech Basic Information List
Table 122. Genentech Description and Business Overview
Table 123. Genentech Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 124. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Genentech (2019-2024)
Table 125. Genentech Recent Developments
Table 126. Hikma Pharmaceuticals Basic Information List
Table 127. Hikma Pharmaceuticals Description and Business Overview
Table 128. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 129. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Hikma Pharmaceuticals (2019-2024)
Table 130. Hikma Pharmaceuticals Recent Developments
Table 131. Hospira Basic Information List
Table 132. Hospira Description and Business Overview
Table 133. Hospira Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 134. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Hospira (2019-2024)
Table 135. Hospira Recent Developments
Table 136. Intas Pharmaceuticals Basic Information List
Table 137. Intas Pharmaceuticals Description and Business Overview
Table 138. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 139. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Intas Pharmaceuticals (2019-2024)
Table 140. Intas Pharmaceuticals Recent Developments
Table 141. Karyopharm Therapeutics Basic Information List
Table 142. Karyopharm Therapeutics Description and Business Overview
Table 143. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 144. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Karyopharm Therapeutics (2019-2024)
Table 145. Karyopharm Therapeutics Recent Developments
Table 146. Kyowa Hakko Kirin Basic Information List
Table 147. Kyowa Hakko Kirin Description and Business Overview
Table 148. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 149. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Kyowa Hakko Kirin (2019-2024)
Table 150. Kyowa Hakko Kirin Recent Developments
Table 151. Ligand Pharmaceuticals Basic Information List
Table 152. Ligand Pharmaceuticals Description and Business Overview
Table 153. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Products, Services and Solutions
Table 154. Revenue (US$ Million) in Drugs for Non-Small Cell Lung Cancer Business of Ligand Pharmaceuticals (2019-2024)
Table 155. Ligand Pharmaceuticals Recent Developments
Table 156. Key Raw Materials Lists
Table 157. Raw Materials Key Suppliers Lists
Table 158. Drugs for Non-Small Cell Lung Cancer Downstream Customers
Table 159. Drugs for Non-Small Cell Lung Cancer Distributors List
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
Table 163. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Drugs for Non-Small Cell Lung Cancer Product Picture
Figure 2. Global Drugs for Non-Small Cell Lung Cancer Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Drugs for Non-Small Cell Lung Cancer Sales Value (2019-2030) & (US$ Million)
Figure 4. Drugs for Non-Small Cell Lung Cancer Report Years Considered
Figure 5. Global Drugs for Non-Small Cell Lung Cancer Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Drugs for Non-Small Cell Lung Cancer Revenue in 2023
Figure 7. Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Radiofrequency Ablation (RFA) Picture
Figure 9. Radiation Therapy Picture
Figure 10. Chemotherapy Picture
Figure 11. Targeted Therapies Picture
Figure 12. Immunotherapy Picture
Figure 13. Global Drugs for Non-Small Cell Lung Cancer Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Drugs for Non-Small Cell Lung Cancer Sales Value Market Share by Type, 2023 & 2030
Figure 15. Product Picture of Hospitals
Figure 16. Product Picture of Clinics
Figure 17. Product Picture of Other
Figure 18. Global Drugs for Non-Small Cell Lung Cancer Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Drugs for Non-Small Cell Lung Cancer Sales Value Market Share by Application, 2023 & 2030
Figure 20. North America Drugs for Non-Small Cell Lung Cancer Sales Value (2019-2030) & (US$ Million)
Figure 21. North America Drugs for Non-Small Cell Lung Cancer Sales Value by Country (%), 2023 VS 2030
Figure 22. Europe Drugs for Non-Small Cell Lung Cancer Sales Value (2019-2030) & (US$ Million)
Figure 23. Europe Drugs for Non-Small Cell Lung Cancer Sales Value by Country (%), 2023 VS 2030
Figure 24. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales Value (2019-2030) & (US$ Million)
Figure 25. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales Value by Country (%), 2023 VS 2030
Figure 26. South America Drugs for Non-Small Cell Lung Cancer Sales Value (2019-2030) & (US$ Million)
Figure 27. South America Drugs for Non-Small Cell Lung Cancer Sales Value by Country (%), 2023 VS 2030
Figure 28. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Sales Value (2019-2030) & (US$ Million)
Figure 29. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Sales Value by Country (%), 2023 VS 2030
Figure 30. Key Countries/Regions Drugs for Non-Small Cell Lung Cancer Sales Value (%), (2019-2030)
Figure 31. United States Drugs for Non-Small Cell Lung Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 32. United States Drugs for Non-Small Cell Lung Cancer Sales Value by Type (%), 2023 VS 2030
Figure 33. United States Drugs for Non-Small Cell Lung Cancer Sales Value by Application (%), 2023 VS 2030
Figure 34. Europe Drugs for Non-Small Cell Lung Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 35. Europe Drugs for Non-Small Cell Lung Cancer Sales Value by Type (%), 2023 VS 2030
Figure 36. Europe Drugs for Non-Small Cell Lung Cancer Sales Value by Application (%), 2023 VS 2030
Figure 37. China Drugs for Non-Small Cell Lung Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 38. China Drugs for Non-Small Cell Lung Cancer Sales Value by Type (%), 2023 VS 2030
Figure 39. China Drugs for Non-Small Cell Lung Cancer Sales Value by Application (%), 2023 VS 2030
Figure 40. Japan Drugs for Non-Small Cell Lung Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 41. Japan Drugs for Non-Small Cell Lung Cancer Sales Value by Type (%), 2023 VS 2030
Figure 42. Japan Drugs for Non-Small Cell Lung Cancer Sales Value by Application (%), 2023 VS 2030
Figure 43. South Korea Drugs for Non-Small Cell Lung Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 44. South Korea Drugs for Non-Small Cell Lung Cancer Sales Value by Type (%), 2023 VS 2030
Figure 45. South Korea Drugs for Non-Small Cell Lung Cancer Sales Value by Application (%), 2023 VS 2030
Figure 46. Southeast Asia Drugs for Non-Small Cell Lung Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Drugs for Non-Small Cell Lung Cancer Sales Value by Type (%), 2023 VS 2030
Figure 48. Southeast Asia Drugs for Non-Small Cell Lung Cancer Sales Value by Application (%), 2023 VS 2030
Figure 49. India Drugs for Non-Small Cell Lung Cancer Sales Value, (2019-2030) & (US$ Million)
Figure 50. India Drugs for Non-Small Cell Lung Cancer Sales Value by Type (%), 2023 VS 2030
Figure 51. India Drugs for Non-Small Cell Lung Cancer Sales Value by Application (%), 2023 VS 2030
Figure 52. Drugs for Non-Small Cell Lung Cancer Industrial Chain
Figure 53. Drugs for Non-Small Cell Lung Cancer Manufacturing Cost Structure
Figure 54. Channels of Distribution (Direct Sales, and Distribution)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
